Brief: Genesis Pharma Announces Distribution Agreement With Deciphera Pharma To Commercialize Ripretinib In 14 EU Markets
12/01/2024 11:37
Jan 12 (Reuters) - Deciphera Pharmaceuticals Inc
DCPH.O :
* GENESIS PHARMA ANNOUNCES AN EXCLUSIVE DISTRIBUTION
AGREEMENT
WITH DECIPHERA PHARMACEUTICALS TO COMMERCIALIZE RIPRETINIB IN 14
EU MARKETS IN CENTRAL AND EASTERN EUROPE
Source text for Eikon: ID:nBw2D1Clpa
Further company coverage: DCPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Deciphera Pharmaceuticals
See all newsBrief: Deciphera Pharmaceuticals Announces Oral Presentation Of Results From Phase 3 Study of Vimseltinib In Patients With Tenosynovial Giant Cell Tumor
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Deals of the day-Mergers and acquisitions